BEVERLY, MA–(Marketwired – Jan 12, 2015) – Cellceutix Corporation (OTCQB: CTIX) (the “Company”) a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antimicrobial applications, invites all interested parties to join the Company during its live webcast presentation at Biotech Showcase 2015 today, Monday, January 12 at 2:00 PM PT (5:00 PM ET). The conference is being held at Parc 55 Wyndham San Francisco (Union Square) in San Francisco, CA on January 12-14, 2015. Cellceutix will be presenting in Room Powell.
Cellceutix Chief Executive Officer Leo Ehrlich, will be giving an introductory overview of the programs at Cellceutix. Thereafter, Cellceutix Chief Operating Officer Dr. James Alexander, will begin with an update on Kevetrin, Cellceutix’s novel anti-cancer compound which is now starting the 10th cohort at 450 mg/m2, and will provide the status and future plans for all of the other drugs in development at Cellceutix, including Brilacidin for Acute Bacterial Skin and Skin Structure Infections, Brilacidin-OM for oral mucositis, Prurisol for psoriasis and other drugs being prepared to enter the clinical stage.
Cellceutix encourages shareholders and other investors to participate in this important presentation by accessing the live webcast through the following link: http://edge.media-server.com/m/p/ya62u49c.
Cellceutix will be publishing an archive of the event on its website under the “Events and Presentations” tab in the “Investors” section. Sign-up for email alerts to be notified immediately when the presentation is available and for all notifications on developments from the Company.